Icon Solutions Welcomes NatWest Executives to its Board of Directors, Accelerating the Expansion of IPF
8.7.2024 13:15:00 EEST | Business Wire | Press release
Icon Solutions today announces it has strengthened and expanded its strategic partnership with NatWest with the appointment of Ian Povey, CIO Payments Technology, and Lee McNabb, Head of Payments Strategy and Partnerships, as Board Observers.
Ian is an experienced and internationally recognised payments product and technology executive. He oversees the modernisation of NatWest’s payments technology estate, with responsibility for the run, change and continuous availability of payments as a systemically critical participant in the industry.
He also serves on the Board of Directors of SWIFT.
Lee has extensive banking experience in product / profit and loss (P&L) management, risk, policy setting and strategy. He joined NatWest in 2018 after 13 years at the Co-operative Bank, latterly owning the payment strategy together with responsibility for regulatory change, including PSD2 and key payment scheme relationships. He is now responsible for the definition and articulation of NatWest’s payments strategy.
The appointments follow NatWest’s strategic investment in Icon Solutions in March 2024. NatWest also announced in September 2023 that it had selected the Icon Payments Framework (IPF) to accelerate the bank’s payments modernisation as it continues to align with the new global ISO 20022 payment data message standards.
Commenting on his appointment, Ian said: “NatWest and Icon have been working collaboratively to modernise payments since 2019. IPF is the payment framework that empowers us to enable change from within and be in control of what we build, so we can deliver new payment services to our customers quickly, safely and cost-efficiently.”
Lee comments: “Our partnership with Icon is key to NatWest’s payments strategy, reflecting our ongoing commitment to investing in and embracing new technologies and capabilities.”
Tom Kelleher, Co-Founder and Commercial Director at Icon, adds: “We are very pleased to welcome Ian and Lee to the Icon Board. Their combined experience and expertise further strengthen our capability to evolve IPF and our services offering to simplify payments transformation.”
Watch this video to learn more about Icon and NatWest’s partnership to modernise payments.
About Icon Solutions
Icon Solutions is a payments solutions company providing financial institutions with technology, payments subject matter expertise and multi-disciplined services. Financial institutions engage these capabilities on their payments transformation journey from defining their payments strategy through to accelerating IPF-based solutions built by their in-house engineering teams, by Icon and/or by a Systems Integrator.
The Icon Payments Framework (IPF) is Icon’s major contribution to the payments industry. It is the framework that underpins payments orchestration solutions and sits at the heart of the core payments architecture of banks such as Citi, NatWest and BNP Paribas. Leveraging the IPF software development kit, banks can easily, quickly and safely deliver payments systems with a low total cost of ownership. IPF also features a range of additional optional modules and ready-made integration to clearing and settlement schemes to accelerate the implementation of end-to-end payments solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240708322216/en/
Contacts
For further Icon media information, please contact Ellie Fingleton at iseepr:
ellie.f@iseepr.co.uk / +44 (0) 113 350 1922
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom